Ask AI
ProCE Banner Activity

CME

Experts Offer Guidance on Shared Decision-making in the Management of Patients With PV/ET

Podcast Episodes

Listen to this audio podcast with myeloproliferative neoplasm experts Joan How, MD and Pankit Vachhani, MD as they discuss the process of shared decision-making (SDM) for the management of patients with PV or ET. They review the benefits of SDM as well as the barriers to effective SDM and offer practical guidance based on their personal experiences.

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: January 26, 2026

Expiration: July 25, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme LLC

Target Audience

This activity is intended for hematologists and other healthcare professionals caring for patients with essential thrombocythemia and polycythemia vera.

Program Learning Goal

This activity aims to improve diagnostic precision, risk stratification, and patient-centered management in essential thrombocythemia and polycythemia vera by strengthening learners’ knowledge, confidence, competence, and performance in applying bone marrow biopsies, prognostic scoring systems, and emerging therapies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement shared decision-making strategies to align treatment goals with patient values, literacy levels, and logistical needs

Disclosure

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Joan How, MD: consultant/advisor/speaker: Merck, PharmaEssentia.

Pankit Vachhani, MD: consultant/advisor/speaker: AbbVie, Amgen, Blueprint Medicines, Cogent Biosciences, DISC Medicine, Genentech, Geron, GSK, Incyte, Kartos, Karyopharm, Merck, Novartis, Pfizer, Servier, Silence Therapeutics, Sobi, Stemline, Syndax, Takeda.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 26, 2026, through July 25, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.